Soquelitinib
Soquelitinib (CPI-818) is an orally active and highly selective covalent interleukin-2-inducible kinase (ITK) inhibitor. Soquelitinib is active in six different models of T cell-mediated inflammatory and immune disease, including acute and chronic asthma, pulmonary fibrosis, systemic sclerosis (scleroderma), psoriasis, and acute graft versus host disease with Th2 cytokine product inhibition. Soquelitinib increases tumor infiltration of normal CD8+ cells that possess enhanced T effector function[1][2][3].
Product Specifications
CAS Number
2226636-04-8
Product Name Alternative
CPI-818
UNSPSC
12352005
Target
Itk
Type
Reference compound
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/soquelitinib.html
Concentration
10mM
Purity
99.71
Solubility
DMSO : ≥ 100 mg/mL
Smiles
O=C(N1C[C@H](N(CCC1)C(C=C)=O)C)C2=C(C=C(C(SC3=CN=C(NC(C4CC4)=O)S3)=C2)C)OC
Molecular Formula
C25H30N4O4S2
Molecular Weight
514.66
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Recombinant Human RPLP2 Protein, N-GST & C-His
RGD1566243 sgRNA CRISPR Lentivector (Rat) (Target 3)
